Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.